Roth MKM Reinstates Buy on Journey Medical, Announces $11 Price Target

Benzinga · 06/28 14:01
Roth MKM analyst Jason Wittes reinstates Journey Medical (NASDAQ:DERM) with a Buy and announces $11 price target.